Correspondence
Eradication Is Impossible
Dtsch Arztebl Int 2010; 107(21): 369. DOI: 10.3238/arztebl.2010.0369a
The authors’ activities for Ardeypharm GmbH are correctly reported as a conflict of interests—the committee at the Robert Koch-Institute cites one of the authors (US) as a “protagonist of the Candida hypothesis” (1). This in itself is not reprehensible—the question it raises is that of appropriate and functioning peer review. How could such an article—which is as medically unenlightening as it is highly suggestive—be published in a renowned journal such as Deutsches Ärzteblatt?
DOI: 10.3238/arztebl.2010.0369a
Prof. Dr. med. Oliver Kurzai
Septomics Research Centre
Friedrich-Schiller-Universität Jena
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie –
Hans-Knöll-Institut
Beutenbergstr. 11 a
07745 Jena, Germany
oliver.kurzai@hki-jena.de
Conflict of interest statement
The author has received research grants from SIRS-Lab and travel expenses and honoraria from Abbott, Gilead, and Pfizer.
1.
Kommission „Methoden und Qualitätssicherung in der Umweltmedizin“: Pathogenetische Bedeutung der intestinalen Candidabesiedlung. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004; 47: 587–600.
2.
Schulze J, Sonnenborn U: Yeasts in the gut: from commensals to infectious agents [Pilze im Darm – von kommensalen Untermietern zu Infektionserregern]. Dtsch Arztebl Int 2009; 106: 837–42. VOLLTEXT
| 1. | Kommission „Methoden und Qualitätssicherung in der Umweltmedizin“: Pathogenetische Bedeutung der intestinalen Candidabesiedlung. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004; 47: 587–600. |
| 2. | Schulze J, Sonnenborn U: Yeasts in the gut: from commensals to infectious agents [Pilze im Darm – von kommensalen Untermietern zu Infektionserregern]. Dtsch Arztebl Int 2009; 106: 837–42. VOLLTEXT |
